Maze Therapeutics’ Post

MZE001 could have great impact on patients and families living with Pompe disease. #Mazetherapeutics #Shionogi #Partnership #Pompedisease #Raredisease #Clinicaltrials #HiRO #Harvestintegratedresearchorganization #CSMA #Pharmacovigilance #Medicalaffairs #Regulatoryaffairs #Datamanagement #Innovation

Type A GABA receptors are the primary inhibitory receptors in the brain and a significant drug target for antidepressants, anesthetics, sedatives, and hypnotics. However, the vast number of GABA A receptor structures that can be formed from a total of 19 different subunits presents a significant challenge to the drug discovery community. We were thrilled to learn of the use of TRC research chemicals in ongoing work probing the structure of GABA A receptor subpopulations, with relevance to drug design, led by Dr Sun Chang at the Vollum Institute in Portland Oregon. Find out more here: https://okt.to/FLiWIb Discover our range of research tools to support your work in this area: https://okt.to/eCZtUy #ProductCitation #GABA #ResearchChemicals #DrugDiscovery #MentalDisorders

Type A GABA receptors are the primary inhibitory receptors in the brain and a significant drug target for antidepressants, anesthetics, sedatives, and hypnotics. However, the vast number of GABA A receptor structures that can be formed from a total of 19 different subunits presents a significant challenge to the drug discovery community. We were thrilled to learn of the use of TRC research chemicals in ongoing work probing the structure of GABA A receptor subpopulations, with relevance to drug design, led by Dr Sun Chang at the Vollum Institute in Portland Oregon. Find out more here: https://okt.to/eL60lz Discover our Toronto Research Chemicals range of research tools to support your work in this area: https://okt.to/LIdDMf #ProductCitation #GABA #ResearchChemicals #DrugDiscovery #MentalDisorders

Improving Passive Membrane Permeability of Cyclic Peptides by Amide-to-Ester Substitution with Jumpei Morimoto from The University of Tokyo. Cyclic peptides are attracting increasing attention as therapeutic modalities. However, their low membrane permeability significantly limits their applications for drug discovery. Recently, our group has shown that amide-to-ester substitution is an effective strategy to improve the membrane permeability of cyclic peptides. In this presentation, I will discuss the effect of amide-to-ester substitution on membrane permeability and conformational dynamics of cyclic peptides. https://lnkd.in/eyDWU6av Save $150 with Discount code SPK150. #drugdiscoverychemistry

#WIKIMOLE THIS WEEK: Mertansine (DM1) - the payload of ADCs! DM1（Mertansine）is a derivative of the natural alkaloid Maytansine. Maytansine is found in the genus Maytenus of the Celastraceae family and related plants, and it exhibits a potent ability to inhibit the proliferation of tumor cells. However, Maytansine is highly active and toxic, easily causing severe side effects. Therefore, medicinal chemists have modified Maytansine to obtain a series of derivatives. Among them, the most widely used are Mertansine DM1 and Mertansine DM4 (Ravtansine). 🎁 Flash Sale:  For U.S. customers, enjoy exclusive 20% discount until January 1. For non-U.S. customers, please check with your local distributors for collective discount pricing. 👉 https://lnkd.in/gBSVEFKX Stay tuned for our weekly revelations and discounts. #WikiMole #MolecularWonders #ScienceDiscovery #TargetMol #Mertansine

Check out Gyrolab for oligonucleotide quantification: high throughput, low volume, highly reproducible and sensitive.

In our new paper on intra-articular drug delivery, we compared the influence of high and low molecular mass hyaluronic acid - natural component of synovial fluid - implemented into model acceptor medium, on the release kinetics of drug chatacterized by limited aqueous solubility: "Influence of the Acceptor Fluid on the Bupivacaine Release from the Prospective Intra-Articular Methylcellulose Hydrogel" (Wójcik-Pastuszka, D., Frąk, A. and Musiał, W., 2024, Pharmaceutics, 16(7), p.867). Congratulations, Dorota and Anna!

Praesidia’s Linker Enzyme Substrate System (LESS™) technology can significantly increase the Therapeutic Index of a drug. Our #MOA video demonstrates how. #Transporters #ChangeMedicine #BBB #TissueTargeting

Piperazine and 1-azabicyclo[2.2.2]octane are both present in a new drug candidate CRN04894. To expand future studies, we have created two sets of analogs to those fragments, which can be solid starting points for your research projects: -Piperazine derivates set ( https://buff.ly/3URMSyD ) -Azabicyclooctane derivates set ( https://buff.ly/3WqFqga ) CRN04894 is a strong and subtype-specific first-in-class nonpeptide MC2R that has shown efficacy in a rat model of adrenocorticotropic hormone (ACTH)-stimulated corticosterone secretion. CRN04894 is now being tested in a first-in-disease Phase Ib/IIa trial in people with ACTH-dependent Cushing's syndrome, as well as a Phase II trial in people with congenital adrenal hyperplasia. Sounds interesting? drop us a line at info@chem-space.com #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

Q. Droperidol, a neuro eptic, belongs to follow ng class of drugs (A) Phenothiazines (B) Thioxanthines (C) Butyrophenone (D) Benzamides